According to results released on Monday, the coronavirus vaccine developed by AstraZeneca and the University of Oxford offered good immunity against Covid-19 in a major clinical trial in the United States, fully preventing the disease’s potential consequences while causing no significant side effects.
The trial, which involved over 32,000 people, was the biggest of its kind for the shot. All in all, the vaccine was 79% effective in avoiding symptomatic infections, which was higher than in earlier clinical studies. The trial also revealed that the vaccine provided adequate protection for elderly people, who were underrepresented in previous research.
On Monday, AstraZeneca said it will continue to review new data and develop to apply to the Food and Drug Administration for emergency approval “in the coming weeks.” It has now been approved in more than 70 countries, but obtaining approval from American authorities, if the business is successful, will improve the vaccine’s global credibility.
Also readWorld Down Syndrome Day : Recognizing Uniqueness
The preliminary findings, which were published on Monday, were focused on 141 Covid-19 cases discovered in volunteers. The vaccine was administered to two-thirds of the subjects in four-week intervals, while the others got a saline placebo. Participants were brought in from Chile, Peru, and the United States.
But the fresh data may not make much difference in the United States, where the vaccine is not yet authorized and may not be needed.
If AstraZeneca is granted emergency use approval in the United States based on the new findings, the vaccine will not be available until May, when three manufacturers that have already been granted authorization are expected to produce enough doses for all of the country’s adults.
Serum Institute of India (SII) manufactures and distributes AstraZenca Vacunder the label “Covishield” in India.
Also read :
